Career history of Jessica Stitt
Former positions of Jessica Stitt
| Companies | Position | Start | End |
|---|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 2021-02-28 | 2022-03-31 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 2020-01-31 | 2020-12-31 |
| THERAVANCE BIOPHARMA, INC. | Public Communications Contact | - | - |
Training of Jessica Stitt
| St. Anselm College | Undergraduate Degree |
| Simmons School of Management | Masters Business Admin |
Statistics
International
| United States | 5 |
| United Kingdom | 2 |
Operational
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
| Public Communications Contact | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| Private companies | 2 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Jessica Stitt
- Experience
